COMPARATIVE BIOEQUIVALENCE STUDIES OF SOME BRANDS OF METRONIDAZOLE TABLETS MARKETED IN ZARIA, NIGERIA
COMPARATIVE BIOEQUIVALENCE STUDIES OF SOME BRANDS OF METRONIDAZOLE TABLETS MARKETED IN ZARIA, NIGERIA
No Thumbnail Available
Date
2014-10
Authors
ALIYU, Shuaibu
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Multisource pharmaceutical products are intended to be pharmaceutically equivalent or
pharmaceutical alternatives that are bioequivalent and hence are therapeutically equivalent
and interchangeable. Thus, this study was aimed at carrying out a comparative in-vitro and
in-vivo bioequivalence studies of some brands of Metronidazole (200 mg) tablets marketed
in Zaria, Nigeria. BP 2002 method was use for the assessment of the pharmaceutical and
chemical equivalences of the samples of metronidazole tablets. Tablet hardness and friability
testing were also carried out to reinforce the official methods for the in vitro studies. The
analytical method for the in vivo studies was adopted from the work of Kolawole and Ameh
(2004). The method was validated according to ICH/WHO guideline. Six healthy human
volunteers were enrolled for the studies according to the normal protocols for bioequivalence
studies. The study yielded the following results: The presence of metronidazole was
observed in all the samples with a content uniformity of 92.45 - 106.16 %. All the samples
had acceptable level of weight variation, except MT05, MT08 and MT12 with 5, 4 and 14
tablets respectively deviated from the mean weight. All the samples disintegrated within 15
minutes (BP specification) with the exception of MT07 which disintegrated in 18.97
minutes. Each of the samples had at least a dissolution of 70 % within 45 minutes. All the
samples had acceptable level of friability, except MT05, MT07, MT08 and MT11 with value
of 1.70 %, 1.81 %, 1.62 % and 10.25 % respectively above the 1 % acceptable limit. All the
samples of the tablets had acceptable hardness within the limit of 4-10 kgF, except MT10
and MT11 with a value of 10.70 kgF and 10.6 kgF respectively. The validated method was
found to have an intra- and inter-day precision of 0.491 and 0.417 % respectively expressed
as percentage relative standard deviation. The accuracy of the method was 1.98 % with a
mean percentage recovery of 98.3 %. All the samples had acceptable level of bioequivalence
within the range of 0.93-1.05 with reference to MT01® as the reference standard using point
estimate ratio of the mean Cmax and AUC0→8h /μg. In conclusion, the samples of the
metronidazole 200 mg tablets analysed can be used interchangeably even though there was
some variation in their pharmaceutical equivalences.
Description
A THESIS SUBMITTED TO THE SCHOOL OF POST GRADUATE STUDIES,
AHMADU BELLO UNIVERSITY, ZARIA
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD
OF A
MASTER DEGREE IN PHARMACEUTICAL CHEMISTRY
DEPARTMENT OF PHARMACEUTICAL AND MEDICINAL CHEMISTRY,
FACULTY OF PHARMACEUTICAL SCIENCES,
AHMADU BELLO UNIVERSITY, ZARIA
OCTOBER, 2014
Keywords
COMPARATIVE,, BIOEQUIVALENCE,, STUDIES,, BRANDS,, METRONIDAZOLE,, TABLETS,, MARKETED,, ZARIA,, NIGERIA